Vestibular Schwannoma Pathophysiology

• Intralabyrinthine schwannoma masking as Meniere's disease
• Balance control and vestibular disorders in pregnant women: A comprehensive review on pathophysiology, clinical features and rational treatment
• Chronic Pain in Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis: A Review on Epidemiology, Pathophysiology, Symptomatology and Treatment
• A fully automatic radiomics pipeline for postoperative facial nerve function prediction of vestibular schwannoma
• Tumour Shrinkage and Good Facial Nerve Function After Planned Partial Resection and Gamma Knife Radiosurgery in Koos 4 Vestibular Schwannoma
• Preoperative cVEMP Results Predict Developing Prolonged Dizziness After Vestibular Schwannoma Surgery
• A morphological features-based nomogram for predicting facial nerve function in the immediate postoperative period after vestibular schwannoma surgery
• NF2-related schwannomatosis: A view from within the inner ear

The pathophysiology of VS involves genetic mutations, cellular dysregulation, and a complex tumor microenvironment. Here’s a closer look at key aspects:

• NF2 Gene Mutation: The most common genetic cause of VS is a mutation in the NF2 gene on chromosome 22, which encodes the tumor suppressor protein merlin (schwannomin). Loss of merlin function is a key factor in VS pathogenesis, as it disrupts cell growth regulation.
• Sporadic vs. Syndromic Cases: Sporadic vestibular schwannomas (unilateral) usually involve a single acquired NF2 mutation, while bilateral VS is characteristic of Neurofibromatosis Type 2 (NF2), an inherited disorder. Patients with NF2 have a higher risk of developing multiple schwannomas and other tumors.

• Loss of Growth Control: Loss of merlin’s function in Schwann cells leads to abnormal cell proliferation and tumor formation. Merlin normally regulates cell adhesion, proliferation, and migration by interacting with various signaling molecules.
• Signal Pathway Dysregulation: In the absence of functional merlin, signaling pathways involved in cell growth and survival, such as PI3K/AKT, MAPK/ERK, and mTOR, become dysregulated, promoting tumor growth.
• ECM Interaction: The extracellular matrix (ECM) composition in VS tumors affects cell adhesion, migration, and proliferation, contributing to tumor development. For instance, ECM proteins like laminin, fibronectin, and collagen influence tumor cell behavior through cell-ECM interactions.

• Vascularization: VS tumors are often highly vascularized, with increased angiogenic factors like VEGF promoting the development of new blood vessels within the tumor. This vascular support aids in tumor growth and sustains Schwann cell survival.
• Immune Microenvironment: The VS tumor microenvironment has immune cells, including macrophages, which may influence tumor progression and immune responses. The immune profile of the tumor is an area of interest in developing targeted therapies.

• Hearing and Balance Dysfunction: As VS grows, it can compress the cochlear (auditory) and vestibular (balance) portions of cranial nerve VIII. This pressure disrupts nerve function, leading to symptoms such as unilateral hearing loss, tinnitus, and balance disturbances.
• Brainstem Compression: Large tumors can exert pressure on adjacent structures like the brainstem and cerebellum, which can lead to more severe neurological symptoms if untreated.

• Inflammatory Cytokines: VS can exhibit increased inflammatory cytokines and oxidative stress markers, which may further drive tumor progression and symptomatology. Inflammatory processes can also impact local blood-brain barrier integrity, affecting tumor behavior.

• Hearing Loss: This is one of the most common symptoms due to direct cochlear nerve compression or disrupted blood flow to the inner ear.
• Tinnitus and Vertigo: Result from disrupted vestibular function and altered neural signaling within the tumor microenvironment.
• Potential for Growth: While many VS remain small and asymptomatic, some can grow and cause significant neurological issues.

Research is actively investigating molecular targets within the NF2 signaling pathway, ECM components, and angiogenesis inhibitors to slow or halt VS growth. Immunotherapy approaches are also being explored, focusing on modulating the immune response in the tumor microenvironment.

A deeper understanding of these pathophysiological mechanisms is critical for developing targeted therapies that can improve outcomes for patients with VS.

The extracellular matrix (ECM) in vestibular schwannomas (VS), also known as acoustic neuromas, plays a crucial role in tumor growth, cell signaling, and cellular microenvironment. VS arising from Schwann cells in the vestibular nerve, and understanding the ECM in these tumors is important for insights into their vestibular schwannoma pathophysiology and potential therapeutic approaches. Here’s an overview:

ECM Composition: In vestibular schwannomas, the ECM consists of various structural proteins (collagen, laminin, fibronectin) and glycoproteins, which provide support and influence cellular behaviors. Collagen IV, laminin, and heparan sulfate proteoglycans are commonly expressed in VS.

Role in Tumor Growth: The ECM in VS may promote tumor cell proliferation and survival through interactions with cell surface receptors, such as integrins. It can also influence cell adhesion, migration, and apoptosis resistance, supporting tumor progression.

Signaling Pathways: ECM components interact with Schwann cells, activating signaling pathways like PI3K/Akt and MAPK/ERK, which can drive cellular proliferation and survival. Alterations in ECM-related genes and signaling proteins are often observed in VS and are thought to contribute to tumor development.

Vascularization and Angiogenesis: ECM plays a role in angiogenesis within vestibular schwannomas. The presence of ECM proteins like fibronectin can support the formation of new blood vessels, aiding tumor growth by increasing nutrient supply.

Potential Therapeutic Targets: Given the ECM’s role in VS, targeting ECM components or the interactions between ECM and tumor cells is a potential therapeutic strategy. Drugs that modify ECM composition or inhibit specific ECM-cell interactions may reduce tumor growth or improve outcomes in VS treatment.

Research in this area is ongoing, with a focus on understanding the specific molecular interactions within the ECM that could be exploited to prevent or slow VS growth.

Larger VS exhibit increased collagen abundance in the tumor stroma, and a more disorganized collagen architecture compared to smaller VS and normal peripheral nerve tissue. This finding indicates that collagen organization may play a significant role in extracellular matrix remodeling and the progression of VS ¹⁾